Search This Blog

Friday, October 30, 2026

Acumen halts sabirnetug development as Phase 2l in early Alzheimer’s fails primary, key secondary endpoints

 

Acumen halts sabirnetug development after Phase 2 ALTITUDE-AD trial in early Alzheimer’s fails primary and key secondary endpoints

  • Acumen will implement cash conservation measures following the discontinuation of sabirnetug development in Alzheimer’s disease.
  • The company is exploring strategic options in the wake of the unsuccessful Phase 2 ALTITUDE-AD trial.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)